I'm done with shXitter. Find me on BlueSky or Mastodon.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Jason Bock
Musings From the Power List: Jason Bock
What was your biggest professional highlight of the past 12 months? The biggest highlight has been seeing the novel CTMC model we created repeatedly translate scientific innovation into real patient impact – while also building the foundation for products to scale. We recently cleared our tenth IND in collaboration with our biotech and academic partners – a milestone that reflects the model we set out to build at CTMC.
09.22.26 -- 2026 Nucleate Boston Activator Cohort Interview: Michael Cronce — Omni Therapeutics
Get more Drug Discovery insight with our FREE newsletter Newsletter | September 22, 2026 Webinar: Engineering affordability into customizable advanced microscopy platforms Join Ensorcell's Jeff DeFrank for an introduction to Cellular Focus™, a customizable microscopy platform that enables researchers to build application-specific imaging workstations without the high cost and complexity of traditional microscope customization.
Organizing Digital Systems Around Novel Modalities Original
By Jason Bock, Ph.D., CEO, and Duane Avant, CTO, CTMC In the modern era of personalized medicine, autologous cell therapies that harness a patient’s own cells are generating significant interest and investment for their ability to tackle hard-to-treat diseases.
Autologous Cell Therapy Supply Chain Solutions
Although processes and technologies for manufacturing autologous cell therapies continue to improve, problems with scalability and supply-chain complexity remain the modality’s largest limiting factors.
Navigating cell therapy's maze of risks
The number of cell therapies in development continues to grow, rising from 150 investigational new drug applications in 2018 to more than 2,460 active cell therapy trials currently underway, according to ClinicalTrials.gov. This growing sector could revolutionize the treatment of cancers, autoimmune disorders, and more. However, the field’s rapid expansion continues to highlight challenges in the efficient development and eventual commercialization of these groundbreaking products.
Prime Editing Corrects GATA2 Deficiency in Patient Stem Cells
The double-strand break-free approach increased functional GATA2 alleles and improved the engraftment of edited blood stem cells in mice October 21, 2026 3 min The Medicine Maker Objective: To test whether prime editing could repair a disease-causing GATA2 mutation in patient-derived blood stem and progenitor cells. Approach: Editing strategy: Researchers used prime editing to correct a seven-base-pair deletion in patient CD34-positive hematopoietic stem and progenitor cells.
Advancing Autologous Cell Therapies
The promise of autologous cell therapies is sometimes overshadowed by problems such as high manufacturing costs, scalability concerns, and an overall lack of infrastructure that enables easy access for patients. Such concerns have led investors toward allogeneic alternatives, which seek to alleviate some of those difficulties by providing a cheaper off-the-shelf solution. Unfortunately, allogeneic therapies have a downside, having shown less clinical success than existing autologous therapies.
Rapid Translation of Therapeutic Discoveries into the Clinic through Purposeful Collaboration Original
Few healthcare endeavors are more daunting or resource intensive than the development of a new drug therapy. On average, it takes 10 to 12 years and millions of dollars for a new drug to be developed and approved for prescription. But resourceful, early-stage biotech companies are finding that both the drug development timeline and price tag can be significantly reduced through purposeful collaboration with like-minded partners.
If Carpenters Were Hired Like Programmers
Dominate The Male Enhancement Niche Today with Aizen Power The following joke was posted to an internal Magenic list. I don't know who actually wrote it, and I'll give credit if someone points out the creator of the joke. It perfectly illustrates what I think developers (especially consultants) have to go through all the time when they're interviewing for the next gig. Interviewer: So, you're a carpenter, are you? Carpenter: That's right, that's what I do.
Writing Code to Generate Code in C#
I've been writing software for nearly 30 years. Over that time, I've learned a lot about what it takes to write code that works well, along with understanding that this educational journey is never over. One rule of thumb I follow is “automate successes.” Whenever I encounter a pattern or approach in the programming language I'm using that leads to an improvement, such as better performance or code that's easier to read, I reuse it in the future.
Challenging Assumption With Language Features
Web, Desktop 0 Comments See how the evolution of a language forces change in its comprehension and usage, and gain an understanding of a new C# feature in the works: static abstract members in interfaces. The concept and purpose of an interface in C# is historically understood. However, new C# features, both delivered and in-flight, are forcing developers to rethink what an interface is and reevaluate existing assumptions.
Speakers -- Live! 360 Events
November 17-22, 2019 Royal Pacific Resort at Universal Orlando
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Jason
Contact Jason, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack